Álvaro Rojas
A5067371298- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Galectins and Cancer Biology
- Bacterial Identification and Susceptibility Testing
- Antibiotic Use and Resistance
- Trypanosoma species research and implications
- Research on Leishmaniasis Studies
- Infective Endocarditis Diagnosis and Management
- Antibiotic Resistance in Bacteria
- Infectious Aortic and Vascular Conditions
- Vascular Procedures and Complications
- Pneumocystis jirovecii pneumonia detection and treatment
- Machine Learning in Bioinformatics
- Reproductive tract infections research
- Endometrial and Cervical Cancer Treatments
- Gender, Violence, Rights in Latin America
- Indigenous Cultures and Socio-Education
- Clostridium difficile and Clostridium perfringens research
- Literary and Cultural Studies
- Biochemical and Structural Characterization
- Basque language and culture studies
- Historical Studies in Science
- Viral gastroenteritis research and epidemiology
- HIV/AIDS Research and Interventions
Pontificia Universidad Católica de Chile
1988-2023
University of Chile
2003-2016
BackgroundThe Global Point Prevalence Survey (Global-PPS) established an international network of hospitals to measure antimicrobial prescribing and resistance worldwide. We aimed assess in hospital inpatients.MethodsWe used a standardised surveillance method collect detailed data about from worldwide, which were grouped by UN region. The internet-based survey included all inpatients (adults, children, neonates) receiving who on the ward at 0800 h one specific day between January September,...
The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports results obtained for healthy Chilean adults aged ≥18 years in phase 3 clinical trial.Volunteers randomly received doses or placebo, separated by weeks. A total 434 volunteers were enrolled, 397 18-59 37 ≥60 years. Solicited unsolicited adverse...
Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are actively carried out around the world. Several vaccines currently approved for emergency use in population, while ongoing studies continue provide information on their safety and effectiveness. CoronaVac is an inactivated SARS-CoV-2 vaccine with a good immunogenicity profile as seen phase 1, 2, 3 clinical trials world, effectiveness of 65.9% symptomatic cases. Although vaccination...
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. rapid development of safe protective vaccines against this disease is global priority. CoronaVac vaccine prototype based on inactivated SARS-CoV-2, which shown promising safety immunogenicity profiles in pre-clinical studies phase 1/2 trials China. To day, four 3 clinical are Brazil, Indonesia, Turkey, Chile. This article reports the results obtained subgroup participants...
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 4 weeks after two doses CoronaVac; these were significantly reduced at 6 to 8 months doses. Here, we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOCs), Delta Omicron, in adults participating phase III clinical trial Chile. Volunteers immunized with...
BackgroundThe Omicron variant has challenged the control of COVID-19 pandemic due to its immuno-evasive properties. The administration a booster dose SARS-CoV-2 vaccine showed positive effects in immunogenicity against SARS-CoV-2, effect that is even enhanced after second booster.MethodsDuring phase-3 clinical trial, we evaluated CoronaVac®, an inactivated administered 6 months first booster, neutralization (n = 87). In parallel, cellular immunity 45) was analyzed stimulated peripheral...
Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe cases. We investigate non-inferiority of two immunization schedules CoronaVac® in a trial healthy adults. A total 2302 adults were enrolled at 8 centers Chile randomly assigned vaccination schedules, receiving doses with either 14 or 28 days between each. The primary efficacy endpoints solicited adverse events...
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials China, Brazil, Indonesia, Turkey, Chile. Methods: This study randomized, multicenter, controlled phase 3 trial healthy Chilean adults aged ≥18 years. Volunteers received two doses...
Carbapenems are the preferred β-lactamics for treatment infections caused by enterobacteria producing extended-spectrum β-lactamases (ESBL); however, clinical studies show effectiveness of piperacillin/tazobactam in certain Escherichia coli ESBL producers.To determine and micro-biological cure with patients E. producers, CTXM type.Retrospective descriptive study adults hospitalized a university hospital. We included urinary tract (UTI), intra-abdominal (IAI), soft tissue (STI) and/or...
Trypanosoma cruzi calreticulin (TcCRT), described in our laboratory, retains several important functional features from its vertebrate homologues.We have shown that recombinant TcCRT inhibits the human complement system when it binds to collagenous portion of C1q.The generation classical pathway convertases and membrane attack complexes is thus strongly inhibited.In most T. cruzi-infected individuals, immunogenic mediates specific antibodies.By reverting C1q / interaction, a parasite immune...
Abstract Background CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- four-weeks after two doses , but are reduced at six to eight months doses. Here we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOC) Delta Omicron in adults participating phase 3 clinical trial Chile. Methods Volunteers immunized...
Incidence of multi-resistant bacteria is an indicator that permits better estimation the magnitude bacterial resistance in hospitals.To evaluate incidence relevant multi-drug resistant intensive care units (ICUs) Chile.Participating hospitals submitted information about number isolates from infected or colonized patients with 7 epidemiologically adult and pediatric ICUs between January 1, 2014 October 31, 2015 bed days occupied these same period was requested. With data calculated per 1,000...
Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center ChileIntroduction: Red Salud UC is Academic health network where from the public private system are followed by a multidisplinary team.Aim: To determine virologic immunologic response after 144 weeks starting first these patients.Methods: A retrospective analysis adult HIV attended between 1992 2011 was performed.Demographic clinical characteristics, therapies data were...
Community-onset bloodstream infections (CO-BSI) caused by gram-negative bacilli are common and associated with significant mortality; those Pseudomonas aeruginosa worse prognosis higher rates of inadequateempirical antibiotic treatment. The aims this study were to describe the characteristics patients CO-BSI P. aeruginosa, identify predictors, develop a predictive score for CO-BSI. Materials/methods: PROBAC is prospective cohort including >14 years BSI from 26 Spanish hospitals between...
Summary The SARS-CoV-2 Omicron variant has challenged the control of COVID-19 pandemic even in highly vaccinated countries. While a second booster mRNA vaccines improved immunity against SARS-CoV-2, humoral and cellular responses induced by an inactivated vaccine have not been studied. In context phase 3 clinical study, we report that CoronaVac ® increased neutralizing response ancestral virus yet showed poor neutralization variant. Additionally, isolated PBMCs displayed equivalent...
To determine the use of endocervical curettage in women with low-grade squamous intraepithelial lesions (LSIL) or atypical cells unknown significance (ASCUS) on Pap smear.A cross-sectional study evaluated at a single center colposcopy service between January 1999 and December 2003 having LSIL ASCUS smear compatible colposcopic examination who underwent curettage. Associations abnormal results lesion topography, age, satisfactory were evaluated. A multivariate logistic regression model was...
Abstract Background Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac ® (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity in previous studies, preventing severe cases. We further investigated efficacy of two immunization schedules a non-inferiority trial healthy adults. Methods This is multi-center randomized clinical trial. Healthy adults were enrolled at eight centers Chile. Participants randomly assigned...
El presente estudio tiene como propósito identificar el modelo de Gestión Coordinada Fronteras en cual interactúa la Aduana Chile, enfocado al paso fronterizo "Sistema Cristo Redentor" con finalidad reconocer avances y retos aduana desarrollo este modelo. Se utilizó una metodología enfoque cualitativo, que considera elementos "teaching case" un caso investigativo tipo exploratorio. constató gestión descentralizado, ha estado continua construcción desde 1984 posterior año 2001 se afianza...